FY2024 EPS Estimates for FibroGen Increased by William Blair

FibroGen, Inc. (NASDAQ:FGEN) – Research analysts at William Blair increased their FY2024 EPS estimates for shares of FibroGen in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will post earnings per share of ($0.86) for the year, up from their prior forecast of ($1.12). William Blair has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. William Blair also issued estimates for FibroGen’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.38) EPS.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the previous year, the company posted ($0.52) earnings per share.

Separately, StockNews.com started coverage on shares of FibroGen in a research note on Thursday. They issued a “hold” rating on the stock.

FibroGen Trading Down 9.5 %

Shares of FGEN opened at $0.33 on Monday. The firm has a market cap of $33.73 million, a P/E ratio of -0.27 and a beta of 0.72. The stock’s 50 day moving average is $0.36 and its two-hundred day moving average is $0.71. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.93.

Institutional Trading of FibroGen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Alpine Global Management LLC acquired a new position in FibroGen in the 1st quarter valued at about $25,000. Delap Wealth Advisory LLC acquired a new stake in shares of FibroGen during the 1st quarter worth about $27,000. Point72 DIFC Ltd raised its holdings in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the period. Doheny Asset Management CA purchased a new position in FibroGen during the second quarter worth about $48,000. Finally, Accel Wealth Management increased its position in shares of FibroGen by 117.5% during the second quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 51,645 shares during the last quarter. 72.71% of the stock is owned by institutional investors and hedge funds.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.